RecruitingPhase 2NCT04888741

Methods of T Cell Depletion Trial (MoTD)

A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide

Sponsor

University of Birmingham

Enrollment

400 participants

Start Date

Feb 22, 2021

Study Type

INTERVENTIONAL

Conditions

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Hodgkin Lymphoma Non-Hodgkin Lymphoma Multiple Myeloma Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia Myelofibrosis Chronic Myelogenous Leukemia

Summary

A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.

Eligibility

Min Age: 16 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cyclophosphamide, a drug called Cyclosporine, and others for people with acute lymphoblastic leukemia, acute myeloid leukemia, and other related conditions. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 16 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGThymoglobulin

GVHD prophylaxis

DRUGCyclophosphamide

Post transplant cyclophosphamide strategy for GVHD prophylaxis

DRUGCyclosporine

immunosuppressant

DRUGSirolimus

immunosuppressant

DRUGMycophenolate Mofetil

immunosuppressant

Locations(17)

University Hospital of Wales

Cardiff, Wales, United Kingdom

Queen Elizabeth Hospital

Birmingham, United Kingdom

Bristol Haematology and Oncology Centre

Bristol, United Kingdom

Addenbrookes Hospital

Cambridge, United Kingdom

Queen Elizabeth Hospital Glasgow

Glasgow, United Kingdom

St Jame's University Hospital

Leeds, United Kingdom

University College London Hospital

London, United Kingdom

King's College Hospital

London, United Kingdom

Hammersmith Hospital

London, United Kingdom

Manchester Royal Infirmary

Manchester, United Kingdom

The Christie

Manchester, United Kingdom

Freeman Hospital

Newcastle upon Tyne, United Kingdom

Nottingham City Hospital

Nottingham, United Kingdom

Churchill Hospital

Oxford, United Kingdom

Derriford Hospital

Plymouth, United Kingdom

Royal Hallamshire Hospital

Sheffield, United Kingdom

The Royal Marsden Hospital

Sutton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04888741

Related Trials

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT063031931 location

CIML NK Cells With Venetoclax for AML

NCT061528092 locations

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

NCT056212918 locations

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT0735407424 locations